<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794660</url>
  </required_header>
  <id_info>
    <org_study_id>CESTA / PP202104-08</org_study_id>
    <nct_id>NCT04794660</nct_id>
  </id_info>
  <brief_title>The Study for the &quot;Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa&quot;</brief_title>
  <acronym>CESTA</acronym>
  <official_title>The Study for the &quot;Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Agency for Research on Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of KwaZulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheikh Anta Diop University, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Agency for Research on Cancer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of CESTA are (1) to compare the efficacy of two cervical cancer screening&#xD;
      algorithms: HPV test followed by visual inspection with acetic acid (VIA) and treatment (HPV&#xD;
      + VIA + treat) and HPV test followed by immediate treatment (HPV + treat). The study will be&#xD;
      conducted to address its objectives in women living with HIV (from now on called HIV positive&#xD;
      women); and 2) to model the comparative cost-effectiveness of the two screening and treatment&#xD;
      strategies.&#xD;
&#xD;
      2,000 HIV positive women will be recruited from HIV care clinics, also called antiretrovirals&#xD;
      (ARV) clinics in South Africa. After giving informed consent, women will be screened with HPV&#xD;
      testing and those that are HPV positive will be randomized at a 4:1 ratio into HPV + VIA +&#xD;
      treat (Arm 1) and HPV + treat (Arm 2). Women in Arm 1 will receive VIA and only positive for&#xD;
      VIA will be treated. In Arm 2, all HPV positive women will be treated. Women that are&#xD;
      eligible for ablative treatment will be randomized into treatment with TA or cryotherapy in&#xD;
      both arms. Others will be referred to colposcopy. After VIA in Arm 1 or before treatment in&#xD;
      Arm 2, the nurses will collect 2-4 biopsies on all HPV positive women. The biopsies will be&#xD;
      used as gold standard for disease detection. Treated women will be called by telephone after&#xD;
      1 week and 1 month to assess side-effects and satisfaction with the procedures. All women who&#xD;
      were HPV-positive (treated or not) will be called back after 1 year for a follow-up visit. At&#xD;
      this visit, women will be screened with HPV testing and VIA and 2-4 colposcopy-directed&#xD;
      biopsies will be taken from all HPV positive women. Women with remaining/recurrent CIN2+&#xD;
      disease will receive appropriate management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Care providers and participants are masked to the intervention ahead of the intervention. However, the strategy delivery is not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of women treated with high grade lesions in both arms</measure>
    <time_frame>up top 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of women treated with low grade lesions in both arms</measure>
    <time_frame>up to 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of HPV infection and lesions at one year</measure>
    <time_frame>up to 14 months</time_frame>
    <description>all HPV positive women at screening will be asked to come back at one year to be tested for HPV. HPV positive women at one year will be refered to colposcopy and biopsies will be taken</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>HPV Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HPV DNA Test</intervention_name>
    <description>Screening for HPV using a HPV DNA test</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VIA triage test</intervention_name>
    <description>VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.&#xD;
After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Treatment by ablative treatment</intervention_name>
    <description>Cryotherapy or Thermal Ablation are performed on the cervix.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colposcopy</intervention_name>
    <description>Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to disclose HIV status&#xD;
&#xD;
          -  HIV negative women aged 30-54 years; HIV positive women aged 25-54 years&#xD;
&#xD;
          -  Mentally competent to give informed consent&#xD;
&#xD;
          -  Physically able to have a pelvic exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women reporting no previous sexual activity&#xD;
&#xD;
          -  History of cervical cancer&#xD;
&#xD;
          -  Treatment for cervical precancer in the last six months&#xD;
&#xD;
          -  Hysterectomy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Serious pre-existing medical conditions (e.g. history of bleeding disorders, serious&#xD;
             physical or mental disease)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Broutet</last_name>
    <role>Principal Investigator</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maribel Almonte</last_name>
    <phone>00472738492</phone>
    <email>AlmonteM@iarc.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roi Baudoin hospital</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamadou Diop</last_name>
      <email>drmdiop@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mamadou Diop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wentworth Hospital</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Motshedisi Sebitloane</last_name>
      <email>Sebitloanem@ukzn.ac.za</email>
    </contact>
    <investigator>
      <last_name>Motshedisi Sebitloane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Senegal</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIA triage</keyword>
  <keyword>HIV serostatus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04794660/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04794660/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

